Pharmacoeconomics of darunavir.
Expert Rev Pharmacoecon Outcomes Res
; 11(1): 27-39, 2011 Feb.
Article
en En
| MEDLINE
| ID: mdl-21351854
ABSTRACT
Darunavir boosted with ritonavir (DRV/r) in combination with other antiretrovirals (ARVs) was initially approved in 2006 for the treatment of HIV infection in ARV treatment-experienced adults and has subsequently been approved for use in treatment-naive adults in 2008. Clinical studies have shown that DRV/r in combination with other ARVs achieves superior levels of undetectable plasma HIV RNA and generates significant CD4 increases, which reduce the risk of HIV disease progression. Economic evaluations, based on data from controlled clinical trials, found DRV/r combination therapy to generate savings in hospital costs and other non-ARV costs of care in treatment-experienced patients, to maximize the number of patients reaching undetectable plasma HIV RNA, to improve health-related quality of life and quality-adjusted life expectancy, and to be cost effective across different patient populations.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Sulfonamidas
/
Infecciones por VIH
/
Inhibidores de la Proteasa del VIH
Tipo de estudio:
Health_economic_evaluation
Aspecto:
Patient_preference
Límite:
Humans
Idioma:
En
Revista:
Expert Rev Pharmacoecon Outcomes Res
Asunto de la revista:
FARMACOLOGIA
Año:
2011
Tipo del documento:
Article
País de afiliación:
Estados Unidos